$106 | SAVE $19 | Single User
$213 | SAVE $37 | Site License
$319 | SAVE $56 | Global License

UCB SA - Financial and Strategic SWOT Analysis Review

UCB SA (UCB) - Financial and Strategic SWOT Analysis Review
[Lowest Price Guaranteed: $106]

Published by Global Data: 13 May 2020 | 260230 | In Stock
Related Topics: Business , Financial , Pharmaceuticals

Introduction

UCB SA (UCB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.

- Corporate strategy – Analyst’s summarization of the company’s business strategy.

- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.

- Company history – Progression of key events associated with the company.

- Major products and services – A list of major products, services and brands of the company.

- Key competitors – A list of key competitors to the company.

- Key employees – A list of the key executives of the company.

- Executive biographies – A brief summary of the executives’ employment history.

- Key operational heads – A list of personnel heading key departments/functions.

- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines include Cimzia for ankylosing spondylitis, axial spondylorthritis, Crohn's disease, psoriatic arthritis and rheumatoid arthritis; Neupro for Parkinson's disease and restless legs syndrome; and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Belgium.

UCB SA Key Recent Developments

Apr 16,2020: RDMD secures million in Series A Financing and announces partnership with UCB in Rare Neurodegenerative Disease

Feb 20,2020: UCB shows strong performance in 2019 and increases the mid-term guidance for two core products

Dec 18,2019: Expanding its portfolio of medicines: UCB to build new biotech manufacturing plant in Belgium

Oct 11,2019: UCB acquires Ra Pharma for .1bn to enrich its rare disease portfolio

Oct 10,2019: UCB to acquire Ra Pharmaceuticals in .1bn deal

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents
for UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

  • Table of Contents

    Table of Contents

    List of Tables

    List of Figures

    Section 1 - About the Company

    UCB SA - Key Facts

    UCB SA - Key Employees

    UCB SA - Key Employee Biographies

    UCB SA - Major Products and Services

    UCB SA - History

    UCB SA - Company Statement

    UCB SA - Locations And Subsidiaries

    Head Office

    Other Locations & Subsidiaries

    Joint Venture

    Section 2 – Company Analysis

    Company Overview

    UCB SA - Business Description

    Product Category: Established Brands

    Overview

    Performance

    Product Category: Immunology

    Overview

    Performance

    Product Category: Neurology

    Overview

    Performance

    Geographical Segment: Europe

    Target Markets

    Performance

    Geographical Segment: International Markets

    Performance

    Geographical Segment: The US

    Performance

    R&D Overview

    UCB SA - Corporate Strategy

    UCB SA - SWOT Analysis

    SWOT Analysis - Overview

    UCB SA - Strengths

    UCB SA - Weaknesses

    UCB SA - Opportunities

    UCB SA - Threats

    UCB SA - Key Competitors

    Section 3 – Company Financial Ratios

    Financial Ratios - Capital Market Ratios

    Financial Ratios - Annual Ratios

    Performance Chart

    Financial Performance

    Financial Ratios - Interim Ratios

    Financial Ratios - Ratio Charts

    Section 4 – Company’s Lifesciences Financial Deals and Alliances

    UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

    UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020

    UCB SA, Recent Deals Summary

    Section 5 – Company’s Recent Developments

    Apr 16, 2020: RDMD secures million in Series A Financing and announces partnership with UCB in Rare Neurodegenerative Disease

    Feb 20, 2020: UCB shows strong performance in 2019 and increases the mid-term guidance for two core products

    Dec 18, 2019: Expanding its portfolio of medicines: UCB to build new biotech manufacturing plant in Belgium

    Oct 11, 2019: UCB acquires Ra Pharma for .1bn to enrich its rare disease portfolio

    Oct 10, 2019: UCB to acquire Ra Pharmaceuticals in .1bn deal

    Aug 21, 2019: Global Biopharma Company UCB supports Cognitant Group to Deliver Visual and Interactive Health Information for Patients

    Jul 25, 2019: UCB’s strong performance enables continued investment into future growth drivers

    Jul 02, 2019: DEARhealth announces collaboration with UCB to improve care delivery through new technology for patients living with epilepsy

    Jun 04, 2019: UCB Boston research is advancing medical innovation

    Mar 12, 2019: Ireland to lead €7 million Parkinson’s research project

    Section 6 – Appendix

    Methodology

    Ratio Definitions

    About GlobalData

    Contact Us

    Disclaimer

List Of Tables
in UCB SA - Financial and Strategic SWOT Analysis Review

List of Tables

UCB SA, Key Facts

UCB SA, Key Employees

UCB SA, Key Employee Biographies

UCB SA, Major Products and Services

UCB SA, History

UCB SA, Subsidiaries

UCB SA, Joint Venture

UCB SA, Key Competitors

UCB SA, Ratios based on current share price

UCB SA, Annual Ratios

UCB SA, Annual Ratios (Cont...1)

UCB SA, Annual Ratios (Cont...2)

UCB SA, Interim Ratios

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020

UCB SA, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List Of Figures, Charts and Diagrams
in UCB SA - Financial and Strategic SWOT Analysis Review

List of Figures

UCB SA, Performance Chart (2015 - 2019)

UCB SA, Ratio Charts

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

Additional Details

Publisher

Global Data

Publisher Information

Reference

260230 |

Number of Pages

63

Report Format

PDF

Global Data Reports

This report is published by Global Data

Download Free Report Summary PDF

UCB SA (UCB) - Financial and Strategic SWOT Analysis Review | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...